Please provide your email address to receive an email when new articles are posted on . The addition of amivantamab-vmjw to chemotherapy extended PFS among a subset of patients with non-small cell ...
Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of ...
Please provide your email address to receive an email when new articles are posted on . A quarter of patients with unresectable or metastatic angiosarcoma responded to a combination of ipilimumab and ...
Treatment with Opdivo (nivolumab) in combination with the novel therapy BMS-986012 demonstrated a median overall survival of 18.7 months and a median progression-free survival of 2.1 months among a ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving ...
Hosted on MSN
New approach for testing multiple treatment combinations at once could aid in development of cancer drugs
MIT researchers have developed a new theoretical framework for studying the mechanisms of treatment interactions. Their approach allows scientists to efficiently estimate how combinations of ...
A new combination of drugs has been discovered that may be effective against one of the deadliest cancers, malignant melanoma. The combination -- pairing a drug targeted against mutations in the BRAF ...
Researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy (BKI) released a study investigating the use of combination checkpoint immunotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results